Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Will Rockwell Medical, Inc. (NASDAQ:RMTI) Surprise This Quarter? - Investor Newswire |
 |
 |
|
An Earnings surprise occurs when a company reports earnings that differ from what analysts had expected. An earnings surprise in either a positive or negative direction can often result in significant stock price movement immediately after the earnings announcement, but can also have a long-term effect as well. Most recently for the quarter ending on 2015-03-31, Rockwell Medical, Inc. (NASDAQ:RMTI) posted a surprise factor of 30%. The company reported actual earnings of $-0.07 which was $0.03 away from what analysts were projecting on a consensus basis. Rockwell Medical, Inc. (NASDAQ:RMTI) is scheduled to next report earnings for the current quarter on 2015-07-30. Analysts are expecting earnings per share of $-0.1. This is based on the 5 sell-side brokerages polled by Zacks Research. Institutional and retail investors alike will be paying close attention to the analyst estimate revisions leading up to the earnings announcement date. Analyst Price Target Wall Street brokerage analysts covering the company are projecting the stock to go to $16.6 on a short term basis. This is the consensus estimate from the 5 sell-side firms included in the Zacks consensus number. The firm seeing the most upside to the stock has a target of 26, while the most conservative price target sees the stock reaching $4. Using Zacks simplified scale, the stock has a mean rating of 2.2. This is the mean calculation of the 2.2 ratings surveyed by Zacks, where 1 represents a Strong Buy and 5 represents a Strong Sell. Three months ago the stock had a 2.2 rating. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. |
